193 related articles for article (PubMed ID: 35171708)
1. Redifferentiating Effect of Larotrectinib in
Groussin L; Theodon H; Bessiene L; Bricaire L; Bonnet-Serrano F; Cochand-Priollet B; Leroy K; Garinet S; Pasmant E; Zerbit J; Seban R; Goldwasser F; Clerc J; Cottereau AS; Huillard O
Thyroid; 2022 May; 32(5):594-598. PubMed ID: 35171708
[TBL] [Abstract][Full Text] [Related]
2. Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.
Syed AR; Gorana A; Nohr E; Yuan XK; Amin MASc P; Ghaznavi S; Lamb D; McIntyre J; Eszlinger M; Paschke R
Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642578
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
4. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
5. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ
J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031
[TBL] [Abstract][Full Text] [Related]
6. Projecting long-term clinical outcomes with larotrectinib compared with immune checkpoint inhibitors in metastatic nonsmall cell lung cancer and differentiated thyroid cancer.
Suh K; Kang A; Ko G; Williamson T; Liao N; Sullivan SD
J Manag Care Spec Pharm; 2024 Jun; 30(6):581-587. PubMed ID: 38824630
[TBL] [Abstract][Full Text] [Related]
7. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
8. Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
Farago AF; Demetri GD
Future Oncol; 2020 Mar; 16(9):417-425. PubMed ID: 32129093
[TBL] [Abstract][Full Text] [Related]
9. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.
Capdevila J; Awada A; Führer-Sakel D; Leboulleux S; Pauwels P
Cancer Treat Rev; 2022 May; 106():102380. PubMed ID: 35305441
[TBL] [Abstract][Full Text] [Related]
10. TRK Inhibitors: Clinical Development of Larotrectinib.
Bhangoo MS; Sigal D
Curr Oncol Rep; 2019 Feb; 21(2):14. PubMed ID: 30715603
[TBL] [Abstract][Full Text] [Related]
11. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies.
Pollack M; Keating K; Wissinger E; Jackson L; Sarnes E; Cuffel B
Curr Med Res Opin; 2021 Jan; 37(1):59-70. PubMed ID: 33148054
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.
Balakirouchenane D; Seban R; Groussin L; Puszkiel A; Cottereau AS; Clerc J; Vidal M; Goldwasser F; Arrondeau J; Blanchet B; Huillard O
Thyroid; 2023 Nov; 33(11):1327-1338. PubMed ID: 37725566
[No Abstract] [Full Text] [Related]
13. An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion.
Bargas S; Mc Leer A; Mondet J; Chabre O; Laramas M
Eur J Endocrinol; 2022 Feb; 186(4):K5-K8. PubMed ID: 35118995
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Waguespack SG; Drilon A; Lin JJ; Brose MS; McDermott R; Almubarak M; Bauman J; Casanova M; Krishnamurthy A; Kummar S; Leyvraz S; Oh DY; Park K; Sohal D; Sherman E; Norenberg R; Silvertown JD; Brega N; Hong DS; Cabanillas ME
Eur J Endocrinol; 2022 Apr; 186(6):631-643. PubMed ID: 35333737
[TBL] [Abstract][Full Text] [Related]
15. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Haddad R; Elisei R; Hoff AO; Liu Z; Pitoia F; Pruneri G; Sadow PM; Soares F; Turk A; Williams MD; Wirth LJ; Cabanillas ME
JAMA Oncol; 2023 Aug; 9(8):1132-1141. PubMed ID: 37289450
[TBL] [Abstract][Full Text] [Related]
17. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib.
Caldwell KJ; De La Cuesta E; Morin C; Pappo A; Helmig S
Pediatr Blood Cancer; 2020 Sep; 67(9):e28330. PubMed ID: 32452122
[TBL] [Abstract][Full Text] [Related]
18. Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract][Full Text] [Related]
19. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
20. Off-target resistance to larotrectinib in two patients with NTRK fusion-positive pediatric solid tumors.
Lu S; Xie W; Zhang Y; Sun F; Huang J; Wang J; Zhu J; Zhen Z; Zhang Y
Ann Oncol; 2023 Nov; 34(11):1065-1067. PubMed ID: 37666486
[No Abstract] [Full Text] [Related]
[Next] [New Search]
